SCHEMBL3592593

SCHEMBL3592593

O=c1[nH][nH]c(=O)c2cc(Cl)ccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 4/20 0.69
PARP1 P09874 2/20 0.59
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 1/20 0.46
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
CHEK1 O14757 1/20 0.44
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.42
METAP2 P50579 1/20 0.42
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612899 0.82 DAO (0.70) DAOPARP1KDM4EGRIN2DGRIN3B
SCHEMBL612900 0.82 DAO (1.00) DAOPARP1ALDH1A1GRIN2DGRIN3B
SCHEMBL9384092 0.74 PARP1 (1.00) DAOPARP1ALDH1A1GRIN2DGRIN3B
SCHEMBL20227580 0.74 PARP1 (0.67) DAOPARP1KDM4EGRIN2DGRIN3B
SCHEMBL17968162 0.74 DAO (0.48) DAOKDM4EALDH1A1HSD17B10GRIN2D
SCHEMBL13527428 0.73 KDM4E (0.48) DAOKDM4EALDH1A1HSD17B10CHEK1
SCHEMBL31507102 0.72 PARP1 (0.49) DAOPARP1ALDH1A1GRIN2DGRIN3B
SCHEMBL183181 0.71 PARP15 (0.50) DAOPARP1KDM4EALDH1A1HSD17B10
SCHEMBL2462837 0.71 KDM4E (0.55) DAOPARP1KDM4EALDH1A1HSD17B10
SCHEMBL28009 0.71 PARP1 (0.59) DAOPARP1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) 2025-07-03 US disclosed
EP-4559521-A2 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2025-05-28 EP disclosed
EP-4404931-B1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) 2025-04-09 EP disclosed
CN-119233820-A Azo compounds for the treatment of fibrotic diseases 乔治-奥古斯特-哥廷根公法基金会大学的大学医学院 2024-12-31 CN disclosed
WO-2024227701-A1 PYRIDAZINE COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Tietze Chemical Consulting UG (haftungsbeschränkt) (DE) 2024-11-07 WO disclosed
EP-4458358-A1 PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY Tietze Chemical Consulting UG (DE) 2024-11-06 EP disclosed
EP-4404931-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) 2024-07-31 EP disclosed
WO-2023222865-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) 2023-11-23 WO disclosed
EP-2137162-B1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-08-01 EP disclosed
EP-2137162-B1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-08-01 EP disclosed
US-8536168-B2 Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway NOVARTIS AG (CH) 2013-09-17 US disclosed
US-8536168-B2 Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway NOVARTIS AG (CH) 2013-09-17 US disclosed
US-8536168-B2 Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway NOVARTIS AG (CH) 2013-09-17 US disclosed
US-20100069368-A1 Organic Compounds and Their Uses NOVARTIS AG (CH) 2010-03-18 US disclosed
US-20100069368-A1 Organic Compounds and Their Uses NOVARTIS AG (CH) 2010-03-18 US disclosed
US-20100069368-A1 Organic Compounds and Their Uses NOVARTIS AG (CH) 2010-03-18 US disclosed
EP-2137162-A1 ORGANIC COMPOUNDS AND THEIR USES Novartis Ag (CH) 2009-12-30 EP disclosed
WO-2008110611-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2008-09-18 WO disclosed
WO-2008110611-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2008-09-18 WO disclosed
US-3933488-A CHEMILUMINESCENCE FUJI PHOTO FILM CO., LTD. (JA) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215004-A1 AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES COL1A1, COL14A1, COL2A1 DAO 259/4885PARP1 4485/4885KDM4E 1205/4885
US-20100069368-A1 Organic Compounds and Their Uses SHH, GLI1, VHL DAO 2935/4885PARP1 2721/4885KDM4E 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.